Testing samples from HPV vaccine trials to understand effectiveness.
Official title: Laboratory testing of biospecimens collected from participants of the NCI’s HPV Vaccine studies.
Funded at Fundacion Inciensa · NIH-11220592 · Data updated 2026-11-12
This study is looking at samples from people who have already received the HPV vaccine to see how well one dose works compared to two doses in preventing cervical cancer, and the findings will help improve future vaccination strategies for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fundacion Inciensa NIH-funded |
| Lab location | 1 site (San Jose, Costa Rica) |
| Project start | September 26, 2024 |
| Project end | September 25, 2025 |
| Funding year | 2024 |
| Award (this year) | $608,967 |
| NIH project number | 261201700012I-P00002-759102200002-1 |
| Project ID | NIH-11220592 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult women who have participated in the NCI's HPV vaccine trials.
✕Less likely to help
Patients who have not participated in the HPV vaccine trials or who are not adult women may not benefit from this research.
What this research studies
This research focuses on analyzing biospecimens collected from participants in clinical trials that are evaluating the effectiveness of one versus two doses of HPV vaccines in preventing cervical cancer. The samples will be tested using advanced genetic sequencing techniques in a certified laboratory in Costa Rica. By examining these samples, researchers aim to gather important data that could inform future vaccination strategies and improve public health outcomes related to HPV. Participants in the trials have already received the HPV vaccine, and their samples will help assess the vaccine's performance.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that enhance the prevention of cervical cancer in women.
How similar studies have gone: Previous research has shown success in using genetic sequencing to evaluate vaccine effectiveness, making this approach promising.
Where this research is happening
-
Fundacion Inciensa
San Jose, Costa Rica Active
Researchers
- Principal investigator: Porras, Carolina — Fundacion Inciensa
- Study coordinator: Porras, Carolina
Related research
Other NIH-funded projects on the same topics.
-
Evaluating the effectiveness of HPV vaccination in preventing cervical cancer
This study is looking at how well the HPV vaccine works by comparing the results of people who got one dose versus two doses, and it's especially focused on helping those at higher risk in Costa Rica to get vaccinated and stay healthy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.